{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-25-000013","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.039634+00:00","generated_at":"2026-05-26T17:21:14.175565+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GeneDx Q4 revenue up 64% YoY to $95.3M; adjusted net income $16.8M; FY2025 guidance $350-360M","bullets":["Q4 revenues $95.3M (+64% YoY); exome/genome revenue $78.8M (+101% YoY).","Q4 adjusted gross margin 70% (vs 56% YoY); exome/genome margin >70%.","Q4 adjusted net income $16.8M (GAAP net income $5.4M); full year adjusted net income $6.7M.","FY2025 guidance: revenue $350M-$360M, exome/genome volume and revenue growth at least 30%.","Cash $142.2M at year-end; Q4 operating cash flow $12.4M including $6.8M appeal recovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-25-000013","json":"https://secwatch.observer/filing/0001818331-25-000013.json","markdown":"https://secwatch.observer/filing/0001818331-25-000013.md","text":"https://secwatch.observer/filing/0001818331-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833125000013/0001818331-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833125000013/wgs-20250218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T17:21:14.175565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}